Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 190

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Hematopoietic Stem-Cell Transplantation for Advanced Systemic Mastocytosis

Open access
Ustun, Celalettin, Reiter, Andreas, Scott, Bart L., Nakamura, Ryotaro, Damaj, Gandhi, Kreil, Sebastian, Shanley, Ryan, Hogan, William J., Perales, Miguel-Angel, Shore, Tsiporah, Baurmann, Herrad, Stuart, Robert, Gruhn, Bernd, Doubek, Michael, Hsu, Jack W., Tholouli, Eleni, Gromke, Tanja, Godley, Lucy A., Pagano, Livio, Gilman, Andrew, Wagner, Eva Maria, Shwayder, Tor, Bornhäuser, Martin, Papadopoulos, Esperanza B., Böhm, Alexandra, Vercellotti, Gregory, Van Lint, Maria Teresa, Schmid, Christoph, Rabitsch, Werner, Pullarkat, Vinod, Legrand, Faezeh, Yakoub-agha, Ibrahim, Saber, Wael, Barrett, John, Hermine, Olivier, Hagglund, Hans, Sperr, Wolfgang R., Popat, Uday, Alyea, Edwin P., Devine, Steven, Deeg, H. Joachim, Weisdorf, Daniel, Akin, Cem, Valent, Peter·2014·Journal of Clinical Oncology

Abstract

Purpose: Advanced systemic mastocytosis (SM), a fatal hematopoietic malignancy characterized by drug resistance, has no standard therapy. The effectiveness of allogeneic hematopoietic stem-cell transplantation (alloHCT) in SM remains unknown. Patients and Methods: In a global effort to define the value of HCT in SM, 57 patients with the following subtypes of SM were evaluated: SM associated with clonal hematologic non–mast cell disorders (SM-AHNMD; n = 38), mast cell leukemia (MCL; n = 12), and aggressive SM (ASM; n = 7). Median age of patients was 46 years (range, 11 to 67 years). Donors were HLA-identical (n = 34), unrelated (n = 17), umbilical cord blood (n = 2), HLA-haploidentical (n = 1), or unknown (n = 3). Thirty-six patients received myeloablative conditioning (MAC), and 21 patients received reduced-intensity conditioning (RIC). Results: Responses in SM were observed in 40 patients (70%), with complete remission in 16 patients (28%). Twelve patients (21%) had stable disease, and five patients (9%) had primary refractory disease. Overall survival (OS) at 3 years was 57% for all patients, 74% for patients with SM-AHNMD, 43% for those with ASM, and 17% for those with MCL. The strongest risk factor for poor OS was MCL. Survival was also lower in patients receiving RIC compared with MAC and in patients having progression compared with patients having stable disease or response. Conclusion: AlloHCT was associated with long-term survival in patients with advanced SM. Although alloHCT may be considered as a viable and potentially curative therapeutic option for advanced SM in the meantime, given that this is a retrospective analysis with no control group, the definitive role of alloHCT will need to be determined by a prospective trial.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2014.55.2018

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 190

Metadata

Authors
Ustun, C., Reiter, A., Scott, B. L., Nakamura, R., Damaj, G., Kreil, S., Shanley, R., Hogan, W. J., Perales, M.-A., Shore, T., Baurmann, H., Stuart, R., Gruhn, B., Doubek, M., Hsu, J. W., Tholouli, E., Gromke, T., Godley, L. A., Pagano, L., Gilman, A., Wagner, E. M., Shwayder, T., Bornhäuser, M., Papadopoulos, E. B., Böhm, A., Vercellotti, G., Van Lint, M. T., Schmid, C., Rabitsch, W., Pullarkat, V., Legrand, F., Yakoub-agha, I., Saber, W., Barrett, J., Hermine, O., Hagglund, H., Sperr, W. R., Popat, U., Alyea, E. P., Devine, S., Deeg, H. J., Weisdorf, D., Akin, C., & Valent, P.
Venue
Journal of Clinical Oncology
Published
2014-10-10
Volume
32
Issue
29
Pages
3264-3274
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2113692004
Cited by
190
References
2
FWCI
7.26
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hematopoietic Stem-Cell Transplantation for Advanced Systemic Mastocytosis. https://app.cochat.ai/papers/10.1200/jco.2014.55.2018
The paper
Ustun, C., Reiter, A., Scott, B. L., Nakamura, R., Damaj, G., Kreil, S., Shanley, R., Hogan, W. J., Perales, M.-A., Shore, T., Baurmann, H., Stuart, R., Gruhn, B., Doubek, M., Hsu, J. W., Tholouli, E., Gromke, T., Godley, L. A., Pagano, L., . . . Valent, P. (2014). Hematopoietic Stem-Cell Transplantation for Advanced Systemic Mastocytosis. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2014.55.2018

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.